Journal of Pain and Symptom Management
February 24, 2020
Sunre Park, Yasuko Sato, Yuka Takita et al.
CONTEXT Mindfulness-based interventions have been receiving growing attention in cancer care. OBJECTIVES The purpose of this randomized controlled trial is to examine the effectiveness of mindfulness-based cognitive therapy (MBCT) for psychological distress (anxiety and depression), fear of cancer recurrence (FCR), fatigue, spiritual wellbeing and quality of life (QOL) in Japanese ambulatory...
Neuropsychopharmacology
February 24, 2020
Chadi G. Abdallah, Lynnette A. Averill, Ralitza Gueorguieva et al.
181 citations
Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized...
PLoS One
February 21, 2020
Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos et al.
81 citations
Psilocybin, a substance mainly found in mushrooms of the genus psilocybe, has been historically used for ritualistic, recreational and, more recently, medicinal purposes. The scientific literature suggests low toxicity, low risk of addiction, overdose, or other causes of injury commonly caused by substances of abuse, with growing interest in the use of this substance for conditions such as...
The Journal of Clinical Pharmacology
February 17, 2020
Paul Glue, Natalie J. Medlicott, Peter Surman et al.
44 citations
Parenteral ketamine has fast‐onset antidepressant and antianxiety effects; however, it causes dissociation, hypertension, and tachycardia shortly after dosing. Ketamine's antidepressant effects may be due to active metabolites rather than to ketamine itself. We hypothesized that oral controlled‐release ketamine tablets would improve safety and tolerability compared with injected ketamine by...
BioPsychoSocial Medicine
February 16, 2020
Kaori Ikeuchi, Hiroshi Ishiguro, Yasunori Nakamura et al.
Abstract Background Although fatigue is a common and distressing symptom in cancer survivors, the mechanism of fatigue is not fully understood. Therefore, this study aims to investigate the relation between the fatigue and mindfulness of breast cancer survivors using anxiety, depression, pain, loneliness, and sleep disturbance as mediators. Methods Path analysis was performed to examine direct...
JMIR Mental Health
February 13, 2020
L. Chavez, K. Kelleher, Natasha Slesnick et al.
Background Homelessness among youth is devastating, with high rates of substance use disorders and mental health comorbidity. Mindfulness-based interventions that include meditation and mindfulness skills training reduce stress and symptoms of anxiety or depression. However, engaging high-risk youth in interventions is challenging. Virtual reality is a more flexible platform for delivering...
Behavioural Brain Research
February 13, 2020
S. Kokane, Ross J. Armant, Carlos A. Bolaños-Guzmán et al.
Ketamine, a dissociative anesthetic and psychedelic compound, has revolutionized the field of psychopharmacology by showing robust, and rapid-acting antidepressant activity in patients suffering from major depressive disorder (MDD), suicidal tendencies, and treatment-resistant depression (TRD). Ketamine’s efficacy, however, is transient, and patients must return to the clinic for repeated...
Neuropharmacology
February 12, 2020
C. Wilson, Shanshan Li, Anthony J. Hannan et al.
Traditional monoaminergic treatments of depression frequently exhibit suboptimal tolerability and effectiveness. The 'short' (s) allele variant of 5-HTTLPR is known to compromise transcriptional efficacy of the serotonin transporter (5-HTT) and can reduce treatment response to traditional antidepressants (e.g. selective serotonin reuptake inhibitors or SSRIs). This study sought to establish the...
Pharmacology, Biochemistry, and Behavior
February 5, 2020
Yan Wei, Lijia Chang, Kenji Hashimoto
157 citations
The robust antidepressant effects of (R,S)-ketamine are among the most important discoveries in mood research over the last half century. Off-label use of (R,S)-ketamine, which is an equal mixture of (R)-ketamine and (S)-ketamine, has become especially popular in the United States (US) for treatment-resistant depression. On March 5, 2019, the US Food and Drug Administration approved an...
Frontiers in Neuroscience
February 4, 2020
Claire J. Foldi, Paul Liknaitzky, M.l. Williams et al.
52 citations
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the...